Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
» Cellectar Reports 33% Overall Response Rate in Phase 2 Interim Data for CLR 131 in Relapsed/Refractory DLBCL Patients
Cellectar Reports 33% Overall Response Rate in Phase 2 Interim Data for CLR 131 in Relapsed/Refractory DLBCL Patients
Cellectar Reports 33% Overall Response Rate in Phase 2 Interim Data for CLR 131 in Relapsed/Refractory DLBCL Patients
Submitted by
admin
on July 18, 2018 - 10:54am
Source:
CP Wire
News Tags:
Cellectar
CLR 131
diffuse large B-cell lymphoma
Headline:
Cellectar Reports 33% Overall Response Rate in Phase 2 Interim Data for CLR 131 in Relapsed/Refractory DLBCL Patients
snippet:
Observed responses to date show overall tumor reduction ranged from 60% to greater than 90%
Company is expanding trial cohort up to 30 additional patients
CLR 131 has orphan drug designation for the treatment of Ewing Sarcoma
Do Not Allow Advertisers to Use My Personal information
